1521O A phase II biomarker-driven study evaluating the clinical efficacy of an MDM2 inhibitor, milademetan, in patients with intimal sarcoma, an ultra-rare cancer with highly life-threatening unmet medical needs (NCCH1806/MK004)

Category Primary study
JournalAnnals of Oncology
Year 2021
This article has no abstract
Epistemonikos ID: ec6c9c9ab9f38f9af8c56d7407d68afed8d3b508
First added on: Feb 13, 2025